Karen Oddo joined Ropes & Gray’s litigation practice group in 2012 and is a registered foreign lawyer in the Hong Kong office. Her practice concentrates on advising clients on internal investigations, due diligence, and compliance programs, particularly with a focus on anti-corruption and anti-bribery matters in Asia. Karen has represented and conducted internal investigations for multinational and U.S.-listed clients across different industries, including pharmaceutical, medical device, technology, manufacturing, and venture capital/private equity. Karen also has a range of experience in complex commercial disputes and securities litigation.
- Represented Fortune 500 U.S. technology company in connection with SEC and internal investigation regarding potential bribery and internal control violations in Thailand.
- Represented numerous multinational clients in the pharmaceutical, medical device, life sciences, banking, and technology sectors in connection with internal investigations and risk assessments relating to the FCPA and U.K. Bribery Act throughout the Asia-Pacific Region, including China, Hong Kong, Indonesia, the Philippines, Malaysia, Singapore, Thailand, and Vietnam.
- Advised numerous multinational private equity firms regarding FCPA, AML, and OFAC risks associated with investments throughout the Asia-Pacific region, establishing portfolio company monitoring and training programs, and in evaluating potential regulatory risks and reporting obligations under U.S. law.
- Advised numerous multinational clients in the pharmaceutical, medical device, and life sciences sectors on developing and implementing anti-corruption and AML policies and procedures.
- Representing a multinational medical instrument manufacturer in connection with review of internal controls for its Korean operations, including in relation to third-party relationships and payments.
- Assessed anti-corruption risk of potential distributor partnership in Korea for a multinational medical device manufacturer.
- Conducted anti-corruption due diligence for an international private equity firm in connection with contemplated acquisition of a Korean pharmaceutical and biotechnology manufacturer (including detailed review of improper rebate and kickback-related issues, analysis of company policies, and in-person interviews of the target company’s management in Korea).
- Conducted anti-corruption due diligence for a U.S. private equity firm in connection with the acquisition of a Korean pharmaceutical manufacturer, and designed post-closing anti-corruption and international risk program.
- Trial team member in commercial leasing dispute involving claims of unfair and deceptive business practices. Assisted in all aspects of trial and witness preparation, motions practice, and trial presentation.
- Represented investors and trustees of residential mortgage-backed securities (“RMBS”) in multiple loan repurchase cases in the state and federal courts of New York and Delaware.
- Represented private equity firms in connection with SEC examinations and third party subpoenas.
- Co-author, “Insight: DOJ Revises Policy on Instant Messaging Apps in Foreign Corrupt Practices Act Enforcement,” Bloomberg Law (April 18, 2019)
- Co-author, “Key Amendment to India’s Anti-Corruption Legislation Has Significant Implications for Multinationals Doing Business in India,” Legal Era (April 2019)
- Co-author, “China’s Blocking Statute Creates New Challenges for Multinational Companies,” FCPA Professor (March 6, 2019)
- Co-author, “Compliance Challenges When Working With JV Partners in China,” The Anti-Corruption Report (September 19, 2018)
- Co-author, “Global Healthcare Compliance: Developments and Trends in Korea’s Anti-Corruption Regulatory Regime,” The Anti-Corruption Report (June 13, 2018)
- Co-author, “Global Health Care Compliance: Spotlight On Korea,” Law360 (April 2, 2018)
- Co-author, “New Burma Act Would Hinder US Investment In Myanmar,” Law360 (December 4, 2017)